Finally you hit the nail on the head. I think to bet on Indian market is not a good option.
Focusing on US, Europe, Japan, HK etc, is top priority. It would not be a good idea to tackle a secondary market via offering a low price.
Just a friendly reminder, MSB, even FDA approval were received next month, I'd bet they would be struggling to survive in a long run, due to constantly burning substantial cash. They were meant to make hefty cash flow from Japan market...
PNV, needs to focus on sales, easy to expand 5 times production capacity by 2025 via investing $25m, still has a good chance to succeed, imo.
Good luck all.
All imo.
PNV - Chart, page-16779
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.07 |
Change
0.030(1.47%) |
Mkt cap ! $1.429B | |||
| Open | High | Low | Value | Volume |
| $2.11 | $2.12 | $2.05 | $2.783M | 1.335M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 19976 | $2.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.07 | 9633 | 3 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| PNV (ASX) Chart |